Healthcare

EXOCOUNTER

MENU

Exosome Counting Technology

ExoCounter

Digital Exosome Counting Technology


ExoCounter (BX-EC3 & BX-PW1) has won iF DESIGN AWARD 2021

<About iF DESIGN AWARD>
The iF DESIGN AWARD 2021 is organized by iF International Forum Design GmbH, the oldest independent design organization in the world, based in Germany, and has been internationally recognized for 68 years since 1953. Submissions are awarded in the nine disciplines, including Product, Packaging, Communication, and Architecture. Entrires undergo examinations based on criteria such as impact, differentiaton, and function. In the 2021 competition, award winners in each category were selected from among approximately 10,000 entires (a record high) submitted from 52 countries/regions after a thorough examination by a 98-member jury, consisting of design experts.
>Detail

New model

New ExoCounter was released in March 2020.
Counting range becomes wider by enhancement of application software.
A smaller and stylish design provides you a flexible installation option.

Joint research for predicting Pre-eclampsia

JVCKENWOOD launched joint research with Oxford University and Sysmex R&D Center Europe GmbH to establish a system for predicting the onset of Pre-eclampsia using exosomes.
>Detail

Key benefits

・Count the number of antigen-specific exosomes.
・Direct quantification, no pre-isolation is required.
・Quantification without a standard sample for normalization is possible.
・Easy operation, no adjustment of equipment setting is required.
・Small sample volume (12.5 μL of serum / plasma).
・A disc is capable for 16 samples.
・Dedicated washer for stable assay.

System components

Work flow

Performances

Collaborations

This technology was developed through collaboration with Keio University School of Medicine, Tokyo Medical University,
and Tokyo Institute of Technology with the support by the Program of Development of Advanced Measurement
and Analysis Systems promoted by the Japan Science and Technology Agency (JST).

 

  • JVCKENWOOD Corporation and Sysmex Corporation have agreed to jointly develop diagnostic instruments
    for the measurement of exosomes in March 2016.
    >Detail (pdf : 152KB)
  • JVCKENWOOD Corporation, The National Cancer Center Japan, Sysmex Corporation and Daiich Sankyo Company Limited have agreed to collaborative research with the aim of raising the quality of cancer diagnosis and treatment.
    >Detail (pdf : 91.4 KB)
  • The research article on digital exosome counting technology ExoCounter was published in an early online release of the US scientific journal Clinical Chemistry on Wednesday, July 18, 2018.
    >Detail

Nanobeads technology in ExoCounter

Immno-nanobeads labeling is one of the key technology in "ExoCounter". We asked Professor Hiroshi Handa (Tokyo Medical University | TMU · Department of Nanoparticle Translational Research) who developed nanobeads technology about "ExoCounter".

My research group is working on developing nano-sized latex beads (SG beads) and magnetic nano-beads (FG beads) that can be used in bio-separators and next-generation biosensors, as well as enhancing their functionality in various applications. We have been undergoing collaborative research with not only academic partners but also industrial partners, seeking to move from basic research to developing practical applications. Our innovative nanobead technology has the ability to identify proteins that bind to pharmaceuticals, and contributes greatly to the field of chemical biology. The most impactful achievement of our research to date was the identification of cereblon, the protein that thalidomide binds to, demonstrating the mechanism of the harmful side effects of thalidomide. We provided evidence that cereblon is the cause of the teratogenesis that occurs by thalidomide. Based on this research, we discovered that thalidomide derivatives that bind to cereblon showed anticancer effects, paving the way for the strategic development of next-generation anticancer drugs.

ExoCounter, which was developed by JVCKENWOOD, uses FG beads as probes for bio-sensing, and detects individual exosomes with specific surface markers. In this system, the similarity of the sizes of exosomes, FG beads and nanostructures of the optical disc used for exosome immobilization ensures high detection precision. In addition, the magnetic material in FG beads enhances the detection signal, which enables high-sensitive detection. This is an outstanding example of the utilization of the properties of FG beads in a new field. Exosomes are currently an important subject of research for various diseases, such as cancer. Exosomes also have great potential for the development of new diagnostic and therapeutic technologies for personalized medicine. I strongly expect that ExoCounter will greatly contribute to the field of exosome research by enabling the accurate quantification of exosomes in various samples.

References

Kabe Y, et al. Development of a Highly Sensitive Device for Counting the Number of Disease-Specific Exosomes in Human Sera.
Clinical chemistry,  (2018). 
>Detail
Kristensen SR, et al. Blu-ray beyond music and movies-novel approach to diagnostics measuring specific extracellular vesicles. J Lab Precis Med. 2018;3:84-84.
Kabe Y, et al. Application of high-performance magnetic nanobeads to biological sensing devices. Anal. Bioanal. Chem.
>Detail

Video

This product is research use only, not for use in diagnostic procedures.
We provide custom measurement services.

"ExoCounter" is a trademark or registered trademark of JVCKENWOOD Corporation.